Andrews M - Search Results

1

MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, Louahed J, Chen W, Woods K, Cebon JS. Vella LJ, et al. Among authors: andrews m. Cancer Immunol Res. 2014 Apr;2(4):351-60. doi: 10.1158/2326-6066.CIR-13-0181. Epub 2014 Jan 17. Cancer Immunol Res. 2014. PMID: 24764582

2

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Vella LJ, Andrews MC, Behren A, Cebon J, Woods K. Vella LJ, et al. Expert Rev Clin Immunol. 2014 Aug;10(8):1107-23. doi: 10.1586/1744666X.2014.929943. Epub 2014 Jun 17. Expert Rev Clin Immunol. 2014. PMID: 24939732 Review.

3

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Andrews MC, Turner N, Boyd J, Roberts AW, Grigg AP, Behren A, Cebon J. Andrews MC, et al. Clin Cancer Res. 2015 Dec 1;21(23):5222-34. doi: 10.1158/1078-0432.CCR-15-0393. Epub 2015 Jul 22. Clin Cancer Res. 2015. PMID: 26202951

4

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.

Parakh S, Murphy C, Lau D, Cebon JS, Andrews MC. Parakh S, et al. Among authors: andrews mc. J Clin Pharm Ther. 2015 Feb;40(1):121-3. doi: 10.1111/jcpt.12229. Epub 2014 Nov 10. J Clin Pharm Ther. 2015. PMID: 25382067

5

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.

Tutuka CSA, Andrews MC, Mariadason JM, Ioannidis P, Hudson C, Cebon J, Behren A. Tutuka CSA, et al. Among authors: andrews mc. Mol Cancer. 2017 Jun 28;16(1):112. doi: 10.1186/s12943-017-0684-x. Mol Cancer. 2017. PMID: 28659148 Free PMC article.

6

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J. Andrews MC, et al. J Clin Oncol. 2013 Dec 10;31(35):e448-51. doi: 10.1200/JCO.2013.50.4118. Epub 2013 Nov 4. J Clin Oncol. 2013. PMID: 24190114 No abstract available.

7

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Lau DK, Andrews MC, Turner N, Azad AA, Davis ID, Cebon JS. Lau DK, et al. Melanoma Res. 2014 Apr;24(2):144-9. doi: 10.1097/CMR.0000000000000036. Melanoma Res. 2014. PMID: 24463460

8

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Vella LJ, Andrews MC, Pasam A, Woods K, Behren A, Cebon JS. Vella LJ, et al. Oncoimmunology. 2014 Jul 3;3(7):e946367. doi: 10.4161/21624011.2014.946367. eCollection 2014. Oncoimmunology. 2014. PMID: 25610732 Free PMC article.

9

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J. Da Gama Duarte J, et al. Among authors: andrews mc. Front Immunol. 2018 Mar 2;9:411. doi: 10.3389/fimmu.2018.00411. eCollection 2018. Front Immunol. 2018. PMID: 29552014 Free PMC article. Clinical Trial.

10

Evolving role of tumor antigens for future melanoma therapies.

Andrews MC, Woods K, Cebon J, Behren A. Andrews MC, et al. Future Oncol. 2014 Jun;10(8):1457-68. doi: 10.2217/fon.14.84. Future Oncol. 2014. PMID: 25052755 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,494 results

Search Page

Filters